Increased brain tissue sodium concentration in Huntington's Disease - A sodium imaging study at 4T

NeuroImage

Volumn 63, Issue 1, 2012, Pages 517-524

  Reetz, Kathrin ^a,b,c   Romanzetti, Sandro ^a   Dogan, Imis ^a,b,c   Saß, Christian ^b,d   Werner, Cornelius J ^b   Schiefer, Johannes ^b   Schulz, Jörg B ^b   Shah, N Jon ^a,b,c  

^a FORSCHUNGSZENTRUM JÜLICH   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c Julich Aachen Research Alliance JARA   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Brain atrophy; Huntington's disease; Sodium imaging; Striatum; Tissue sodium concentration

Indexed keywords

SODIUM;

ADULT; AMYGDALOID NUCLEUS; ARTICLE; BRAIN ATROPHY; BRAIN LEVEL; BRAIN REGION; BRAIN TISSUE; CAG REPEAT; CEREBELLUM; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATIONAL STUDY; FEMALE; GLOBUS PALLIDUS; GRAY MATTER; HETEROZYGOSITY; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; IMAGE ANALYSIS; IN VIVO STUDY; INSULA; MALE; MOTOR PERFORMANCE; NERVE DEGENERATION; NEUROIMAGING; NEUROLOGIC EXAMINATION; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL CORTEX; POSTCENTRAL GYRUS; PRECUNEUS; PRIMARY MOTOR CORTEX; PRIORITY JOURNAL; PUTAMEN; TEMPORAL CORTEX; THALAMUS; TISSUE DISTRIBUTION; TOTAL FUNCTIONAL CAPACITY SCORE; VOXEL BASED MORPHOMETRY;

ADULT; BIOLOGICAL MARKERS; BRAIN; FEMALE; HUMANS; HUNTINGTON DISEASE; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SODIUM;

EID: 84864397941     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2012.07.009     Document Type: Article

References (56)

1. Ashburner J., Friston K.J. Unified segmentation. Neuroimage 2005, 26:839-851.
2. Aylward E.H., Li Q., Stine O.C., Ranen N., Sherr M., Barta P.E., Bylsma F.W., Pearlson G.D., Ross C.A. Longitudinal change in basal ganglia volume in patients with Huntington's disease. Neurology 1997, 48:394-399.
3. Balleine B.W., Liljeholm M., Ostlund S.B. The integrative function of the basal ganglia in instrumental conditioning. Behav. Brain Res. 2009, 199:43-52.
4. Boada F.E., Christensen J.D., Huang-Hellinger F.R., Reese T.G., Thulborn K.R. Quantitative in vivo tissue sodium concentration maps: the effects of biexponential relaxation. Magn. Reson. Med. 1994, 32:219-223.
5. Boada F.E., LaVerde G., Jungreis C., Nemoto E., Tanase C., Hancu I. Loss of cell ion homeostasis and cell viability in the brain: what sodium MRI can tell us. Curr. Top. Dev. Biol. 2005, 70:77-101.
6. Browne S.E., Beal M.F. Oxidative damage in Huntington's disease pathogenesis. Antioxid. Redox Signal. 2006, 8:2061-2073.
7. Christensen J.D., Barrere B.J., Boada F.E., Vevea J.M., Thulborn K.R. Quantitative tissue sodium concentration mapping of normal rat brain. Magn. Reson. Med. 1996, 36:83-89.
8. DiFiglia M., Sapp E., Chase K.O., Davies S.W., Bates G.P., Vonsattel J.P., Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277:1990-1993.
9. Dogan, I., Eickhoff, S.B., Schulz, J.B., Shah, N.J., Laird, A.R., Fox, P.T., Reetz, K., in press. Consistent neurodegeneration and its association with clinical progression in Huntington's disease: a coordinate-based meta-analysis. Neurodegener. Dis. http://dx.doi.org/339528.
10. Duran R., Barrero F.J., Morales B., Luna J.D., Ramirez M., Vives F. Oxidative stress and plasma aminopeptidase activity in Huntington's disease. J. Neural Transm. 2010, 117:325-332.
11. Eidelberg D., Surmeier D.J. Brain networks in Huntington disease. J. Clin. Invest. 2011, 121:484-492.
12. Feigin A., Tang C., Ma Y., Mattis P., Zgaljardic D., Guttman M., Paulsen J.S., Dhawan V., Eidelberg D. Thalamic metabolism and symptom onset in preclinical Huntington's disease. Brain 2007, 130:2858-2867.
13. Gabery S., Murphy K., Schultz K., Loy C.T., McCusker E., Kirik D., Halliday G., Petersen A. Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses. Acta Neuropathol. 2010, 120:777-788.
14. Graham R.K., Deng Y., Slow E.J., Haigh B., Bissada N., Lu G., Pearson J., Shehadeh J., Bertram L., Murphy Z., Warby S.C., Doty C.N., Roy S., Wellington C.L., Leavitt B.R., Raymond L.A., Nicholson D.W., Hayden M.R. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 2006, 125:1179-1191.
15. Gramsbergen J.B., Veenma-Van der Duin L., Venema K., Korf J. Cerebral cation shifts and amino acids in Huntington's disease. Arch. Neurol. 1986, 43:1276-1281.
16. Hancu I., Boada F.E., Shen G.X. Three-dimensional triple-quantum-filtered (23)Na imaging of in vivo human brain. Magn. Reson. Med. 1999, 42:1146-1154.
17. Harris G.J., Codori A.M., Lewis R.F., Schmidt E., Bedi A., Brandt J. Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease. Brain 1999, 122(Pt 9):1667-1678.
18. Heinsen H., Rub U., Gangnus D., Jungkunz G., Bauer M., Ulmar G., Bethke B., Schuler M., Bocker F., Eisenmenger W., Gotz M., Strik M. Nerve cell loss in the thalamic centromedian-parafascicular complex in patients with Huntington's disease. Acta Neuropathol. 1996, 91:161-168.
19. Henley S.M., Wild E.J., Hobbs N.Z., Scahill R.I., Ridgway G.R., Macmanus D.G., Barker R.A., Fox N.C., Tabrizi S.J. Relationship between CAG repeat length and brain volume in premanifest and early Huntington's disease. J. Neurol. 2009, 256:203-212.
20. Hilbert D. Über die stetige Abbildung einer Linie auf ein Flächenstück. Math. Ann. 1891, 459-460.
21. Horn M. 23Na magnetic resonance imaging for the determination of myocardial viability: the status and the challenges. Curr. Vasc. Pharmacol. 2004, 2:329-333.
22. Huntington Study Group Unified Huntington's Disease Rating Scale: reliability and consistency. Mov. Disord. 1996, 11:136-142.
23. IEC, Particular requirements for the safety of magnetic resonce equipment for medical diagnosis. IEC 60601-2-33 Medical electrical equipment - Part 2-33.
24. Inglese M., Madelin G., Oesingmann N., Babb J.S., Wu W., Stoeckel B., Herbert J., Johnson G. Brain tissue sodium concentration in multiple sclerosis: a sodium imaging study at 3 tesla. Brain 2010, 133:847-857.
25. Jancso G., Karcsu S., Kiraly E., Szebeni A., Toth L., Bacsy E., Joo F., Parducz A. Neurotoxin induced nerve cell degeneration: possible involvement of calcium. Brain Res. 1984, 295:211-216.
26. Kemp-Harper R., Styles P., Wimperis S. Three-dimensional triple-quantum filtration 23Na NMR imaging. J. Magn. Reson. B 1995, 108:280-284.
27. Kipps C.M., Duggins A.J., Mahant N., Gomes L., Ashburner J., McCusker E.A. Progression of structural neuropathology in preclinical Huntington's disease: a tensor based morphometry study. J. Neurol. Neurosurg. Psychiatry 2005, 76:650-655.
28. Klepac N., Relja M., Klepac R., Hecimovic S., Babic T., Trkulja V. Oxidative stress parameters in plasma of Huntington's disease patients, asymptomatic Huntington's disease gene carriers and healthy subjects: a cross-sectional study. J. Neurol. 2007, 254:1676-1683.
29. Korf J., Gramsbergen J.B., Prenen G.H., Go K.G. Cation shifts and excitotoxins in Alzheimer and Huntington disease and experimental brain damage. Prog. Brain Res. 1986, 70:213-226.
30. Maldjian J.A., Laurienti P.J., Kraft R.A., Burdette J.H. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage 2003, 19:1233-1239.
31. Mascalchi M., Lolli F., Della Nave R., Tessa C., Petralli R., Gavazzi C., Politi L.S., Macucci M., Filippi M., Piacentini S. Huntington disease: volumetric, diffusion-weighted, and magnetization transfer MR imaging of brain. Radiology 2004, 232:867-873.
32. Mellon E.A., Pilkinton D.T., Clark C.M., Elliott M.A., Witschey W.R., Borthakur A., Reddy R. Sodium MR imaging detection of mild Alzheimer disease: preliminary study. AJNR Am. J. Neuroradiol. 2009, 30:978-984.
33. Nielles-Vallespin S., Weber M.A., Bock M., Bongers A., Speier P., Combs S.E., Wohrle J., Lehmann-Horn F., Essig M., Schad L.R. 3D radial projection technique with ultrashort echo times for sodium MRI: clinical applications in human brain and skeletal muscle. Magn. Reson. Med. 2007, 57:74-81.
34. Nopoulos P., Magnotta V.A., Mikos A., Paulson H., Andreasen N.C., Paulsen J.S. Morphology of the cerebral cortex in preclinical Huntington's disease. Am. J. Psychiatry 2007, 164:1428-1434.
35. Paulsen J.S., Langbehn D.R., Stout J.C., Aylward E., Ross C.A., Nance M., Guttman M., Johnson S., MacDonald M., Beglinger L.J., Duff K., Kayson E., Biglan K., Shoulson I., Oakes D., Hayden M. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J. Neurol. Neurosurg. Psychiatry 2008, 79:874-880.
36. Petersen A., Bjorkqvist M. Hypothalamic-endocrine aspects in Huntington's disease. Eur. J. Neurosci. 2006, 24:961-967.
37. Reiner A., Albin R.L., Anderson K.D., D'Amato C.J., Penney J.B., Young A.B. Differential loss of striatal projection neurons in Huntington disease. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:5733-5737.
38. Romanzetti S., Shah N.J. In vivo Quantification of Tissue Sodium Concentration in the Human Brain by Means of a Centric SPRITE Sequence at 4T 2011, International Society for Magnetic resonance in Medicine (ISMRM), Montreal, Canada.
39. Rosas H.D., Hevelone N.D., Zaleta A.K., Greve D.N., Salat D.H., Fischl B. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 2005, 65:745-747.
40. Rosas H.D., Reuter M., Doros G., Lee S.Y., Triggs T., Malarick K., Fischl B., Salat D.H., Hersch S.M. A tale of two factors: what determines the rate of progression in Huntington's disease? A longitudinal MRI study. Mov. Disord. 2011, 26:1691-1697.
41. Sapp E., Kegel K.B., Aronin N., Yohyama K., Uchiyama Y., Bhide P., Vonsattel J.P., DiFiglia M. Microglia accumulate in the HD striatum and cortex. Soc. Neurosci. 1999, 25:829.
42. Schanne F.A., Kane A.B., Young E.E., Farber J.L. Calcium dependence of toxic cell death: a final common pathway. Science 1979, 206:700-702.
43. Shah N.J., Kaffanke J.B., Romanzetti S. Repetition time and flip angle variation in SPRITE imaging for acquisition time and SAR reduction. J. Magn. Reson. 2009, 199:136-145.
44. Shah N.J., Kaffanke J.B., Romanzetti S. Bildgebungsverfahren 2011, Deutsches Patent- und Markenamt, Germany.
45. Shoulson I., Fahn S. Huntington disease: clinical care and evaluation. Neurology 1979, 29:1-3.
46. Tabrizi S.J., Scahill R.I., Durr A., Roos R.A., Leavitt B.R., Jones R., Landwehrmeyer G.B., Fox N.C., Johnson H., Hicks S.L., Kennard C., Craufurd D., Frost C., Langbehn D.R., Reilmann R., Stout J.C. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol. 2011, 10:31-42.
47. Thieben M.J., Duggins A.J., Good C.D., Gomes L., Mahant N., Richards F., McCusker E., Frackowiak R.S. The distribution of structural neuropathology in pre-clinical Huntington's disease. Brain 2002, 125:1815-1828.
48. Thu D.C., Oorschot D.E., Tippett L.J., Nana A.L., Hogg V.M., Synek B.J., Luthi-Carter R., Waldvogel H.J., Faull R.L. Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington's disease. Brain 2010, 133:1094-1110.
49. Thulborn K.R., Gindin T.S., Davis D., Erb P. Comprehensive MR imaging protocol for stroke management: tissue sodium concentration as a measure of tissue viability in nonhuman primate studies and in clinical studies. Radiology 1999, 213:156-166.
50. Thulborn K.R., Lu A., Atkinson I.C., Damen F., Villano J.L. Quantitative sodium MR imaging and sodium bioscales for the management of brain tumors. Neuroimaging Clin. N. Am. 2009, 19:615-624.
51. Vonsattel J.P. Huntington disease models and human neuropathology: similarities and differences. Acta Neuropathol. 2008, 115:55-69.
52. Vonsattel J.P., DiFiglia M. Huntington disease. J. Neuropathol. Exp. Neurol. 1998, 57:369-384.
53. Weir D.W., Sturrock A., Leavitt B.R. Development of biomarkers for Huntington's disease. Lancet Neurol. 2011, 10:573-590.
54. Wheeler V.C., White J.K., Gutekunst C.A., Vrbanac V., Weaver M., Li X.J., Li S.H., Yi H., Vonsattel J.P., Gusella J.F., Hersch S., Auerbach W., Joyner A.L., MacDonald M.E. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum. Mol. Genet. 2000, 9:503-513.
55. Woessner D. NMR relaxation of spin-(3)/(2) nuclei: effects of structure, order, and dynamics in aqueous heterogeneous systems. Concepts Magn. Reson. 2001, 13(5):294-325.
56. Yu Z.X., Li S.H., Evans J., Pillarisetti A., Li H., Li X.J. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. J. Neurosci. 2003, 23:2193-2202.